Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design.
about
Cryoelectron tomography of HIV-1 envelope spikes: further evidence for tripod-like legsNew approaches to eliciting protective immunity through T cell repertoire manipulation: the concept of thymic vaccinationImmunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamstersNatural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary virusesEffects of fungal N- and O-linked mannosylation on the immunogenicity of model vaccinesAntibody-based inhibitors of HIV infection.Problems and emerging approaches in HIV/AIDS vaccine development.Innovative bioinformatic approaches for developing peptide-based vaccines against hypervariable viruses.Models of RNA virus evolution and their roles in vaccine design.Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis.Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding.Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice.Immune response in rhesus macaques after mixed modality immunisations with DNA, recombinant adenovirus and recombinant gp120 from human immunodeficiency virus type 1.Multiprotein genetic vaccine in the SIV-Macaca animal model: a promising approach to generate sterilizing immunity to HIV infection.
P2860
Q21090520-02F622A0-B608-451A-89F3-36EF4533E4F5Q24800305-873E5A54-08FC-4BEF-B008-E8F18F9698E1Q33262275-1613D25B-4869-415F-A2EB-3E3D28D301D6Q34625185-EEECBAEA-33A4-479B-BB23-DAFB489D3C51Q35569049-84F892A0-2F80-4F2D-85DF-7675BC0F375BQ36026319-7A328239-84DB-428F-934C-78161ED18D64Q36446952-8C17928D-9877-47F2-812A-734F7FB7EAEEQ36758574-5339BEE1-2D9E-4F83-9F0A-E8A3866FBCDBQ37748492-07559BA7-8759-4C38-BE58-9F5F3FC61CB8Q37808509-EFB4274E-8D23-4F48-B8F8-1FBED4942E00Q40147993-46DDE19C-4A27-41CF-A96F-17A0EBBE9884Q40340474-0C8D1338-7331-4662-9BD7-ABDA6C6C8C5CQ42121728-129DA3A0-1376-4E4B-8226-3C554570CAD2Q45411816-DD0AEBCA-CD38-4D17-ACF5-C1DF1ED007A4Q53536913-717012F6-A857-43BF-B855-6D00F0B2D7A3
P2860
Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design.
description
2004 nî lūn-bûn
@nan
2004 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Neutralizing antibody response ...... challenges for vaccine design.
@ast
Neutralizing antibody response ...... challenges for vaccine design.
@en
type
label
Neutralizing antibody response ...... challenges for vaccine design.
@ast
Neutralizing antibody response ...... challenges for vaccine design.
@en
prefLabel
Neutralizing antibody response ...... challenges for vaccine design.
@ast
Neutralizing antibody response ...... challenges for vaccine design.
@en
P2093
P2860
P356
P1476
Neutralizing antibody response ...... challenges for vaccine design.
@en
P2093
Indresh K Srivastava
Jeffrey B Ulmer
Susan W Barnett
P2860
P304
P356
10.1586/14760584.3.4.S33
P433
P577
2004-08-01T00:00:00Z